Efficacy, Safety, Tolerability of Carbavance Compared to Piperacillin/Tazobactam in cUTIs, Including AP, in Adults

Bio2RDF uri

Efficacy, Safety, Tolerability of Carbavance Compared to Piperacillin/Tazobactam in cUTIs, Including AP, in Adults

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02166476

Bio2RDF identifier

NCT02166476

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02166476

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02166476

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

850

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02166476 arm group 0181beeccf20f4d28c957a27ac292feb [clinicaltrials_resource:NCT02166476/arm-group/0181beeccf20f4d28c957a27ac292feb]

NCT02166476 arm group 4b683805405633ac0a07d39a9194f3e7 [clinicaltrials_resource:NCT02166476/arm-group/4b683805405633ac0a07d39a9194f3e7]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Carbavance™, (meropenem ...... tions or Acute Pyelonephritis

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy, Safety, Tolerability ...... cUTIs, Including AP, in Adults

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Efficacy measured at the End of IV Treatment visit (FDA), or at the Test Of Cure visit (EMA). EOIVT at day 5 - 14 (FDA), TOC at day 15-23 (EMA) [clinicaltrials_resource:ef88bb882595f8f01fd203b2224bb255]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Efficacy measured at the End of IV Treatment visit (FDA), or at the Test Of Cure visit (EMA). EOIVT at day 5 - 14 (FDA), TOC at day 15-23 (EMA) [clinicaltrials_resource:579bb5e1370873019e43ecb713540fd7]

Efficacy measured at the End of IV Treatment visit (FDA), or at the Test Of Cure visit (EMA). EOIVT at day 5 - 14 (FDA), TOC at day 15-23 (EMA) [clinicaltrials_resource:a39fc18245a5c5994027e25170f0ff11]

Efficacy measured at the End of IV Treatment visit (FDA), or at the Test Of Cure visit (EMA). EOIVT at day 5 - 14 (FDA), TOC at day 15-23 (EMA) [clinicaltrials_resource:c70b205afecc5b2f399161a48a343ff4]

Efficacy measured at the End of IV Treatment visit (FDA), or at the Test Of Cure visit (EMA). EOIVT at day 5 - 14 (FDA), TOC at day 15-23 (EMA) [clinicaltrials_resource:d528a0541ff4d6d97b3580a12abbe6ce]

Efficacy measured at the End of IV Treatment visit (FDA), or at the Test Of Cure visit (EMA). EOIVT at day 5 - 14 (FDA), TOC at day 15-23 (EMA) [clinicaltrials_resource:e047c33fd7428bcb152dc23b62f1aa98]

Efficacy measured at the End of IV Treatment visit (FDA), or at the Test Of Cure visit (EMA). EOIVT at day 5 - 14 (FDA), TOC at day 15-23 (EMA) [clinicaltrials_resource:eb21d2bac80fe4a2042899069d14ccf1]

collaborator [clinicaltrials_vocabulary:collaborator]

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) [clinicaltrials_resource:f6526d7b262d84fb664be56824973e77]

completion date [clinicaltrials_vocabulary:completion-date]

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

In the current era of i ...... nt of adults with cUTI or AP.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02166476 [clinicaltrials_resource:561ac44a95ab29b33cabe79cfab23b3a]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Levofloxacin oral [clinicaltrials_resource:b6d5e1f557c202138168d083bbe511f1]

Piperacillin/tazobactam [clinicaltrials_resource:bd60e0c4169b27bd330a712fea6c18c7]

Carbavance [clinicaltrials_resource:ee9849e71efd44e5f554a5761c889a2c]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Levofloxacin [clinicaltrials_resource:0ac59089609de32eee184f9421659e70]

Tazobactam [clinicaltrials_resource:4172e7173fb233dc48052a8353e2b2f6]

Piperacillin-tazobactam combination product [clinicaltrials_resource:649e2341cd89f077f9af484ac7bc63a0]

Piperacillin [clinicaltrials_resource:9c5e205504208c74bb80cacf4ffc2493]

Penicillanic Acid [clinicaltrials_resource:aaeba07067ec3548e0321e574b4d09df]

Meropenem [clinicaltrials_resource:b17a497a3ee8c699c337d0a2a116cbde]

Ofloxacin [clinicaltrials_resource:bdd661c031084442c69d71aafd9a5455]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) [clinicaltrials_resource:f6526d7b262d84fb664be56824973e77]

location [clinicaltrials_vocabulary:location]

[clinicaltrials_resource:f5cf565098533e911e529293217b0be6]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02166476

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase 3, Multi-Center, Rando ...... cUTIs, Including AP, in Adults

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

Rempex 505

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Jeffery Loutit [clinicaltrials_resource:3c8e61565d5b0f9178c7326ba711939d]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Jeffery Loutit [clinicaltrials_resource:45ce93b17c8188065a05c73dc2bf7826]

overall official [clinicaltrials_vocabulary:overall-official]

Jeffery Loutit [clinicaltrials_resource:61f040cee270915155a2f63cd1d88bb1]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) [clinicaltrials_resource:f6526d7b262d84fb664be56824973e77]

start date [clinicaltrials_vocabulary:start-date]

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02166476 study design [clinicaltrials_resource:c16ca2ae81b0d45c0d7026eb3e4b7777]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02166476

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02166476

http://www.w3.org/2001/XMLSchema#string

title

Efficacy, Safety, Tolerability ...... cUTIs, Including AP, in Adults

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3